%0 Case Reports
%T Brolucizumab after failure of aflibercept with photodynamic therapy in polypoidal choroidal vasculopathy: A case report.
%A Yuan PH
%A Khan HM
%A Sumita FAG
%A Ribeiro Monteiro ML
%A Preti RC
%A Navajas EV
%J Arch Soc Esp Oftalmol (Engl Ed)
%V 98
%N 12
%D 2023 Dec 10
%M 37951353
暂无%R 10.1016/j.oftale.2023.10.009
%X We describe one case of polypoidal choroidal vasculopathy with persistent subretinal fluid despite multiple treatment with intravitreal Bevacizumab, Ranibizumab and Aflibercept, as well as Aflibercept associated with photodynamic therapy. The patient reached complete resolution after intravitreal Brolucizumab injection, but experienced recurrence of subretinal fluid 12 weeks after discontinuation. Brolucizumab might be an option in treating subretinal fluid after failure of other anti-VEGF agents associated with photodynamic therapy.